Dr. Amarnath Chamkur, M.D.
Pediatrics (Pediatrics Physician)
At a glance
- In the NPI registry since
- 2007
Licensed in Texas since 2007, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
TX license M7900 (first issued 2007; active) -
Neonatal-Perinatal Medicine Physician
TX license M7900 (first issued 2007; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $286,289 in research payments for these studies, mostly to the institutions running them.
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06397768 - A phase 2 randomized partially doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine administered in healthy toddlers 12 through 15 months of age
Pfizer Inc. - Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sanofi Pasteur Inc. · Active, not recruiting · NCT06824194 - A phase 2, randomized, double-blind, multi-dose, dose finding study to
GlaxoSmithKline, LLC. - A phase 3A, observer-blind, randomized, controlled study to demonstrat
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.